Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04171141 · ClinicalTrials.gov registry record · Phase 1
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
NCT04171141 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 79 participants.
The verdict
NCT04171141, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
Study Summary
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
Interventions
- DRUG Anti-VEGF
- DRUG PF-07062119
- DRUG Anti-PD1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2019-11-19 |
| Est. Completion | 2023-11-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04171141
The ClinicalTrials.gov registry entry for NCT04171141 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Anti-VEGF is the first listed.
NCT04171141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04171141 about?
NCT04171141 is a clinical study titled "Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.". A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
What is the current status of trial NCT04171141?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2019-11-19. Estimated completion is 2023-11-28.
What interventions are being tested in trial NCT04171141?
The interventions under investigation include: Anti-VEGF (DRUG), PF-07062119 (DRUG), Anti-PD1 (DRUG).
Who is sponsoring clinical trial NCT04171141?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.